I would like to learn more about GenesisĀ® RPA and the physician practice outline above.
Specialties > Pulmonary > COPD (Chronic Obstructive Pulmonary Disease)
Among key components, should optimally include:
FLT4 ā FMS RELATED RECEPTOR TYROSINE KINASE 4
PDB Code: 4BSK
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Proactive Regeneration > High-Stress Lifestyle
Among key components, should optimally include:
GDF11 ā GROWTH DIFFERENTIATION FACTOR 11
PDB Code: 5E4G
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Proactive Regeneration > Common Lifestyle
Among key components, should optimally include:
GDF11 ā GROWTH DIFFERENTIATION FACTOR 11
PDB Code: 5E4G
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Orthopedic > Wrist
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Orthopedic > Thoracic
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Orthopedic > Stellate Ganglion Blocks
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Orthopedic > Shoulder
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Orthopedic > Lumbar
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Orthopedic > Knee
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Orthopedic > Hip
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Orthopedic > Hand
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Orthopedic > Ganglion Impair
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Orthopedic > Foot
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Orthopedic > Facet Joints
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Orthopedic > Elbow
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Orthopedic > Cervical Disks
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Orthopedic > Ankle
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Ophthalmology > Macular Degeneration
Among key components, should optimally include:
NTF3 ā NEUROTROPHIN 3
PDB Code: 3BUK
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Neurological > Thoracic
Among key components, should optimally include:
GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Neurological > Thoracic
Among key components, should optimally include:
GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Neurological > Stroke
Among key components, should optimally include:
GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Neurological > Stellate Ganglion Blocks
Among key components, should optimally include:
GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Neurological > Spinal Cord Injury
Among key components, should optimally include:
GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Neurological > Peripheral Neuropathy
Among key components, should optimally include:
GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Neurological > Depression/Addiction/Detox
Among key components, should optimally include:
GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Neurological > Neurodegenerative Disorder
Among key components, should optimally include:
GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Neurological > Facet Joints
Among key components, should optimally include:
GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Neurological > Cervical Discs
Among key components, should optimally include:
GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Cosmetic > Wounds
Among key components, should optimally include:
EGFR ā EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Cosmetic > Ulcers
Among key components, should optimally include:
EGFR ā EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Cosmetic > Neck
Among key components, should optimally include:
EGFR ā EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Cosmetic > Leg
Among key components, should optimally include:
EGFR ā EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Cosmetic > Skin
Among key components, should optimally include:
EGFR ā EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Cosmetic > Hair
Among key components, should optimally include:
EGFR ā EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Cosmetic > Face
Among key components, should optimally include:
EGFR ā EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Cosmetic > Burns
Among key components, should optimally include:
EGFR ā EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Cosmetic > Anti-Aging
Among key components, should optimally include:
GDF11 ā GROWTH DIFFERENTIATION FACTOR 11
PDB Code: 5E4G
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Cosmetic > Arm
Among key components, should optimally include:
EGFR ā EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Chiropractic > Wrist
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Chiropractic > Thoracic
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Chiropractic > Stellate Ganglion Blocks
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Chiropractic > Shoulder
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Chiropractic > Lumbar
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Chiropractic > Knee
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Chiropractic > Hip
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Chiropractic > Hand
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Chiropractic > Ganglion Impair
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Chiropractic > Foot
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Chiropractic > Facet Joints
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Chiropractic > Elbow
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Chiropractic > Cervical Disks
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Chiropractic > Ankle
Among key components, should optimally include:
BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Cardiological > Vasculature
Among key components, should optimally include:
VEGFA – VASCULAR ENDOTHELIAL GROWTH FACTOR A
PDB Code: 6ZFL
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Cardiological > Myocardial Infarction
Among key components, should optimally include:
VEGFA – VASCULAR ENDOTHELIAL GROWTH FACTOR A
PDB Code: 6ZFL
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Cardiological > Peripheral Arterial Disease
Among key components, should optimally include:
VEGFA – VASCULAR ENDOTHELIAL GROWTH FACTOR A
PDB Code: 6ZFL
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
-
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
</ul class=”cutome-font”>
-
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Cardiological > Peripheral Neuropathy
Among key components, should optimally include:
VEGFA – VASCULAR ENDOTHELIAL GROWTH FACTOR A
PDB Code: 6ZFL
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Auto-Immune > Parkinsonās
Among key components, should optimally include:
IL6 ā INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Auto-Immune > Thyroid
Among key components, should optimally include:
IL6 ā INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Auto-Immune > Rheumatoid Arthritis (RA)
Among key components, should optimally include:
IL6 ā INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Auto-Immune > Multiple Sclerosis (MS)
Among key components, should optimally include:
IL6 ā INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Auto-Immune > Irritable Bowel Syndrome (IBS)
Among key components, should optimally include:
IL6 ā INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Auto-Immune > Hashimotoās
Among key components, should optimally include:
IL6 ā INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Auto-Immune > Fibromyalgia
Among key components, should optimally include:
IL6 ā INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Auto-immune > Diabetes
Among key components, should optimally include:
IL6 ā INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Auto-Immune > Autism (Non-Acute)
Among key components, should optimally include:
IL6 ā INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source ā National Institute of Health > National Library of Medicine
- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Auto-Immune > Crohn’s
Among key components, should optimally include:
IL6 ā INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Auto-Immune > Autism (Acute)
Among key components, should optimally include:
IL6 ā INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source ā National Institute of Health > National Library of Medicine
- *Lumbar puncture for severe older patients
- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Advanced Protocols > Custom Protocol
TNFRSF1B ā TNF RECEPTOR SUPERFAMILY MEMBER 1B
PDB Code: 3ALQ
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Neurological > Ganglion Impair
Among key components, should optimally include:
GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.
Specialties > Neurological > Lumbar
Among key components, should optimally include:
GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source ā National Institute of Health > National Library of Medicine

- If/as applicable, scaffolding optional but not necessary.
- Applications spread over consecutive months unless otherwise specified by clinician.
- Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 ā release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 ā ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ ā resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
- Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
- Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
- Regenerative messages naturally process to areas of highest need first and induce a personās own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to ā for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
- Normal activity and pharmaceuticals at discretion of physician.
Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.